United Therapeutics Corporation Sales Revenue, Services, Net (Deprecated 2018-01-31)
United Therapeutics Corporation (UTHR) reported Sales Revenue, Services, Net (Deprecated 2018-01-31) of $3.08 million for the 3-month period ending 2011-03-31, per its 10-Q filed 2011-04-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueServicesNet · last filed 2011-04-28
- United Therapeutics Corporation sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2011-03-31 was $3.08M, a 5.44% increase year-over-year.
- United Therapeutics Corporation sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2010-12-31 was $2.74M, a 1.52% increase year-over-year.
- United Therapeutics Corporation sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2010-09-30 was $2.34M, a 18.57% decline year-over-year.
- United Therapeutics Corporation sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2010-06-30 was $2.75M, a 3.89% increase year-over-year.
- United Therapeutics Corporation sales revenue, services, net (deprecated 2018-01-31) for fiscal 2010 was $10.75M, a 0.02% increase from fiscal 2009.
- United Therapeutics Corporation sales revenue, services, net (deprecated 2018-01-31) for fiscal 2009 was $10.75M, a 16.13% increase from fiscal 2008.
- United Therapeutics Corporation sales revenue, services, net (deprecated 2018-01-31) for fiscal 2008 was $9.26M.
| Period end | Sales Revenue, Services, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2011-03-31 | $3.08M 10-Q · filed 2011-04-28 | $5.82M derived: sum of 2 quarters · filed 2011-04-28 | $8.16M derived: sum of 3 quarters · filed 2011-04-28 | $10.91M derived: sum of 4 quarters · filed 2011-04-28 |
| 2010-12-31 | $2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-24 | $5.08M derived: sum of 2 quarters · filed 2011-02-24 | $7.83M derived: sum of 3 quarters · filed 2011-02-24 | $10.75M 10-K · filed 2011-02-24 |
| 2010-09-30 | $2.34M 10-Q · filed 2010-10-28 | $5.09M derived: sum of 2 quarters · filed 2010-10-28 | $8.02M 10-Q · filed 2010-10-28 | $10.71M derived: sum of 4 quarters · filed 2011-04-28 |
| 2010-06-30 | $2.75M 10-Q · filed 2010-07-28 | $5.67M 10-Q · filed 2010-07-28 | $8.37M derived: sum of 3 quarters · filed 2011-04-28 | $11.25M derived: sum of 4 quarters · filed 2011-04-28 |
| 2010-03-31 | $2.92M 10-Q · filed 2011-04-28 | $5.62M derived: sum of 2 quarters · filed 2011-04-28 | $8.50M derived: sum of 3 quarters · filed 2011-04-28 | $11.14M derived: sum of 4 quarters · filed 2011-04-28 |
| 2009-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-24 | $5.57M derived: sum of 2 quarters · filed 2011-02-24 | $8.22M derived: sum of 3 quarters · filed 2011-02-24 | $10.75M 10-K · filed 2011-02-24 |
| 2009-09-30 | $2.88M 10-Q · filed 2010-10-28 | $5.52M derived: sum of 2 quarters · filed 2010-10-28 | $8.05M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | $2.65M 10-Q · filed 2010-07-28 | $5.18M 10-Q · filed 2010-07-28 | ||
| 2008-12-31 | $9.26M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |